FINWIRES · TerminalLIVE
FINWIRES

Intrepid Metals股價上漲，因延長了Tombstone South期權協議

By

-- Intrepid Metals (INTR.V) 週三宣布，已與 New Empire Exploration LLC 達成協議，修訂雙方於 2021 年 4 月 20 日簽署的選擇權協議，以收購位於亞利桑那州的 Tombstone South 礦產項目 100% 的權益。 該公司表示，修訂後的協議將原定於 2026 年 5 月到期的 150 萬美元工作承諾的完成期限延長至 2027 年 5 月，作為交換，Intrepid 將向 New Empire Exploration LLC 發行 20 萬股普通股，並額外支付 5 萬美元。上述款項均已支付給 New Empire Exploration LLC。 該公司還表示，原定於 2027 年 5 月到期的 150 萬美元額外工作承諾保持不變，並補充說，該修訂尚需獲得多倫多證券交易所創業板 (TSX Venture Exchange) 的批准。 該公司表示，Tombstone South礦區是一個碳酸鹽交代礦床（CRD）或矽卡岩型鋅銀鉛礦目標，與位於西南方向60公里處的South 32礦區的Taylor礦床類似。該公司計劃通過第一階段鑽探計劃對這一新目標進行測試，該計劃將從四到五個鑽井平台鑽探約4,000公尺。 「Tombstone South礦區位於一個已探明的碳酸鹽交代礦床（CRD）區域內，是一個極具前景且勘探程度較低的礦區，」Intrepid公司董事長兼臨時首席執行官Matt Lennox-King表示。 「先前的地球物理勘探發現，在比斯比地層與賦存鋅鉛銀泰勒硫化物礦床（South32 Limited公司所有，位於西南約75公里處）的石灰岩單元接觸帶附近存在顯著的極化率異常。自2025年12月以來，公司已籌集超過1910萬加元的資金，我們目前處於有利地位，並期待推進該項目。」 該公司股票在多倫多證券交易所創業板（TSX Venture Exchange）的最新交易價格上漲0.02加元，至0.80加元。

Price: $0.80, Change: $+0.02, Percent Change: +2.56%

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Lucid Group Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target to $6 from $10. Following a weaker-than-expected Q1 earnings release, we are maintaining a Hold opinion on LCID shares. We revise our adjusted EPS estimates to -$12.00 from -$12.70 for '26 and to -$11.10 from -$11.45 for '27. LCID posted Q1 adjusted EPS of -$2.82 vs. -$2.04, well short of the -$2.30 consensus. Revenue rose 20% to $282.5M ($76.0M below consensus) in Q1, led by higher prices, as total vehicle sales fell 1% to 3,093 units. In the release, LCID did not provide any update regarding prior 2026 vehicle production guidance of 25K-27K units (an implied increase over the 17,840 units produced in 2025). In our view, LCID's accelerating cash burn and rising inventories suggest ongoing risks. The company's ability to achieve sustainable growth while managing its substantial cash requirements remains the critical challenge as it seeks to establish a viable position in the competitive luxury EV market; however, a $1.5B capital raise last month helps extend its liquidity runway.

$LCID
Research

Research Alert: CFRA Maintains Sell Opinion On Shares Of Celanese Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 earnings, we raise our 12-month target price by $2 to $43 on a forward P/E of 7.4x our 2027 EPS view of $5.78, a discount to the three-year average of 10.4x justified by CE's high debt levels and subdued demand. We raise our 2026 EPS view by $1.35 to $6.14 and decrease 2027's by $0.09 to 5.78. Our sales estimates are $9.7 billion for 2026 and $10.1 billion for 2027. On the positive side, CE's Acetyl Chain's Q2 2026 Adjusted EBIT guidance of $300M-$325M was solid, led by higher expected volumes and prices. However, the acetate tow business remains weak and feedstock costs have risen sharply. Meanwhile, Engineered Materials' Q2 2026 Adjusted EBIT guidance of $190M-$210M was more conservative due to inventory reductions and additional costs from the POM facility turnaround. Overall, we believe CE's 48% year-to-date stock gain is excessive and expect earnings to decline once again in 2027 as the temporary margin boost from the Middle East conflict fades.

$CE
Treasury

Canada's Provincial Budgets in Pain From Healthcare Costs, Says CIBC

The COVID-19 pandemic may be distant in the rearview mirror, but healthcare costs in Canada are continuing to have an outsized impact on provincial finances, said CIBC.At just over 40% of total expenses in aggregate, healthcare is always the single biggest line item, writes the bank in a note to clients. However, its recent impact has been even greater than that, as it has contributed more than half of the increases in spending seen in the past five years.In addition, these cost increases haven't always been easy to predict, with healthcare also contributing more than 50% of recent spending overshoots relative to initial budget estimates, points out CIBC.Increased health spending needs have often been blamed on inflation, including pay increases for medical staff and population growth. While concerns about inflationary pressures are resurfacing again due to the Middle East conflict, the sharp deceleration in population growth should, in theory, ease the strain on healthcare costs.Unfortunately, however, there is another and potentially larger factor driving costs upwards, one that will get worse before it gets better. That's the increase in healthcare costs that comes from an aging population, as per capita health spending rises exponentially for age brackets above 65, states the bank.If the population continues to age as expected, then healthcare costs could continue to rise more than provinces, on aggregate, are currently projecting, according to CIBC.

$$CXY